SFI
CYTK icon

Susquehanna Fundamental Investments’s Cytokinetics CYTK Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,387
Closed -$779K – 796
2025
Q1 		$779K Sell
19,387
-112,412
-85% -$5.17M 0.01% 750
2024
Q4 		$6.2M Buy
+131,799
New +$6.84M 0.09% 288
2024
Q2 		$6.79M Buy
125,271
+58,195
+87% +$3.51M 0.16% 176
2024
Q1 		$4.7M Buy
+67,076
New +$5.19M 0.22% 122
2023
Q1 		– Sell
-23,072
Closed -$1.06M – 984
2022
Q4 		$1.06M Buy
23,072
+12,289
+114% +$529K 0.02% 643
2022
Q3 		$522K Buy
+10,783
New +$519K 0.01% 1003
2022
Q1 		$1.03M Buy
28,130
+9,440
+51% +$335K 0.02% 827
2021
Q4 		$852K Buy
18,690
+5,690
+44% +$220K 0.02% 711
2021
Q3 		$465K Buy
+13,000
New +$383K 0.01% 1247

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Susquehanna Fundamental Investments's CYTK Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 19,387 shares — an estimated $779K sold.

Susquehanna Fundamental Investments first reported a position in CYTK in Q3 2021 and held it in 9 quarters. The position peaked at $6.79M in Q2 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 19,387 Cytokinetics shares in Q2 2025, an estimated $779K.
  • Susquehanna Fundamental Investments first reported a position in Cytokinetics in Q3 2021 and held it in 9 quarters.
  • Susquehanna Fundamental Investments's Cytokinetics position peaked at $6.79M in Q2 2024.
  • 311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.